...
机译:C-myc表达和成熟表型与另外的Ixazomib向骨髓瘤中的Lenalalomide-dexamethasone相关的结果效果有关
Millennium Pharmaceuticals Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company;
Southern Alberta Cancer Research InstituteUniversity of CalgaryCalgary AB Canada;
Hematologic OncologyDana‐Farber Cancer InstituteBoston MA USA;
HematologyIUC‐OncopoleToulouse France;
Department of Haematology and Stem Cell TransplantationSt. István and St. László Hospital of;
Instituto Português de Oncologia do Porto Francisco Gentil Entidade Pública Empresarial (IPOPFG;
Hematology and OncologyUniversity Hospital BrnoBrno Czech Republic;
Department of HaematologyChristchurch HospitalChristchurch New Zealand;
Institute of Hematology and Medical Oncology "Seràgnoli"Bologna University School of;
University Hospital of UlmUlm Germany;
Division of HematologyMayo ClinicRochester MN USA;
Division of HematologyMayo ClinicRochester MN USA;
Translational Genomics Research Institute (TGEN)Phoenix AZ USA;
Millennium Pharmaceuticals Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company;
Millennium Pharmaceuticals Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company;
Millennium Pharmaceuticals Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company;
Millennium Pharmaceuticals Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company;
Millennium Pharmaceuticals Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company;
Millennium Pharmaceuticals Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company;
Millennium Pharmaceuticals Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company;
Millennium Pharmaceuticals Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company;
Millennium Pharmaceuticals Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company;
Hematologic OncologyDana‐Farber Cancer InstituteBoston MA USA;
Department of HematologyUniversity Hospital H?tel DieuNantes France;
c‐myc Proto‐Oncogenes; multiple myeloma; mutation; progression‐free survival; RNA sequencing;
机译:C-myc表达和成熟表型与另外的Ixazomib向骨髓瘤中的Lenalalomide-dexamethasone相关的结果效果有关
机译:较高的c-MYC表达与依沙米单抗-来那度胺-地塞米松(IRd)无进展生存期(PFS)相对于安慰剂-Rd的关联:电气石-MM1期3期研究在复发/难治性多发性骨髓瘤(RRMM)中的生物标志物分析
机译:在常规临床实践中复发和难治多骨髓瘤患者的LenaLazomib,LenaLalomide和Dexamethasone(IRD)对Lenalymide和Dexamethasone(RD)的生存益处
机译:多孔壳聚糖支架中双相磷酸钙的添加对体外成骨细胞表型表达的影响
机译:在常规临床实践中复发和难治多骨髓瘤(RD)对Lenalalomide和地塞米松(IRD)的肝氮杂胺和地塞米松(IRD)的生存益处
机译:在常规临床实践中复发和难治多骨髓瘤(RD)对Lenalalomide和地塞米松(IRD)的肝氮杂胺和地塞米松(IRD)的生存益处